11/24
07:25 pm
crmd
Assessing CorMedix (CRMD): Is the Current Share Price Reflecting Its True Value? [Yahoo! Finance]
Medium
Report
Assessing CorMedix (CRMD): Is the Current Share Price Reflecting Its True Value? [Yahoo! Finance]
11/20
08:10 pm
crmd
Cormedix Inc (CRMD) Q3 2025 Earnings Call Highlights: Record Financial Performance and ... [Yahoo! Finance]
Low
Report
Cormedix Inc (CRMD) Q3 2025 Earnings Call Highlights: Record Financial Performance and ... [Yahoo! Finance]
11/18
07:06 pm
crmd
Does the Recent 9.9% Pullback Make CorMedix a Bargain in 2025? [Yahoo! Finance]
Low
Report
Does the Recent 9.9% Pullback Make CorMedix a Bargain in 2025? [Yahoo! Finance]
11/18
06:38 am
crmd
Buy Rating Reaffirmed: CorMedix Inc. (CRMD) Posts Profitability and Expands Outlook for 2025 [Yahoo! Finance]
Low
Report
Buy Rating Reaffirmed: CorMedix Inc. (CRMD) Posts Profitability and Expands Outlook for 2025 [Yahoo! Finance]
11/18
05:22 am
crmd
H.C. Wainwright Raises the PT on ?CorMedix Inc. (CRMD), Keeps a Buy [Yahoo! Finance]
Low
Report
H.C. Wainwright Raises the PT on ?CorMedix Inc. (CRMD), Keeps a Buy [Yahoo! Finance]
11/14
02:57 pm
crmd
CorMedix: Raised Guidance, NOL Confidence, And Rezzayo Optionality Justify A Hold Rating [Seeking Alpha]
Low
Report
CorMedix: Raised Guidance, NOL Confidence, And Rezzayo Optionality Justify A Hold Rating [Seeking Alpha]
11/13
08:11 am
crmd
CorMedix (NASDAQ:CRMD) had its price target raised by analysts at HC Wainwright from $17.00 to $18.00. They now have a "buy" rating on the stock.
Low
Report
CorMedix (NASDAQ:CRMD) had its price target raised by analysts at HC Wainwright from $17.00 to $18.00. They now have a "buy" rating on the stock.
11/12
07:14 pm
crmd
Talphera signals study completion in first half of 2026 as new site activations delay NEPHRO timeline [Seeking Alpha]
Low
Report
Talphera signals study completion in first half of 2026 as new site activations delay NEPHRO timeline [Seeking Alpha]
11/12
02:21 pm
crmd
CorMedix (NASDAQ:CRMD) had its price target lowered by analysts at Needham & Company LLC from $20.00 to $16.00. They now have a "buy" rating on the stock.
Low
Report
CorMedix (NASDAQ:CRMD) had its price target lowered by analysts at Needham & Company LLC from $20.00 to $16.00. They now have a "buy" rating on the stock.
11/12
02:21 pm
crmd
CorMedix (NASDAQ:CRMD) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $14.00 price target on the stock.
Low
Report
CorMedix (NASDAQ:CRMD) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $14.00 price target on the stock.
11/12
11:13 am
crmd
CorMedix Inc. (CRMD) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
CorMedix Inc. (CRMD) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/12
11:13 am
crmd
CorMedix raises 2025 revenue guidance to $390M-$410M amid accelerated Melinta integration and DefenCath momentum [Seeking Alpha]
Medium
Report
CorMedix raises 2025 revenue guidance to $390M-$410M amid accelerated Melinta integration and DefenCath momentum [Seeking Alpha]
11/12
08:21 am
crmd
CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance [Yahoo! Finance]
Medium
Report
CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance [Yahoo! Finance]
11/12
07:34 am
crmd
CorMedix GAAP EPS of $1.26 beats by $0.63, revenue of $104.28M beats by $18.26M [Seeking Alpha]
Medium
Report
CorMedix GAAP EPS of $1.26 beats by $0.63, revenue of $104.28M beats by $18.26M [Seeking Alpha]
11/12
07:30 am
crmd
CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance
Low
Report
CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance
11/10
08:57 am
crmd
Assessing CorMedix (CRMD) Valuation After Recent Momentum Pause and Melinta Therapeutics Acquisition [Yahoo! Finance]
Low
Report
Assessing CorMedix (CRMD) Valuation After Recent Momentum Pause and Melinta Therapeutics Acquisition [Yahoo! Finance]
11/6
06:56 am
crmd
CorMedix (NASDAQ:CRMD) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Medium
Report
CorMedix (NASDAQ:CRMD) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
10/31
08:30 am
crmd
CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025
Medium
Report
CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025
10/25
11:32 pm
crmd
Assessing CorMedix (CRMD) Valuation Following Recent Share Price Fluctuations [Yahoo! Finance]
Low
Report
Assessing CorMedix (CRMD) Valuation Following Recent Share Price Fluctuations [Yahoo! Finance]
10/23
08:30 am
crmd
CorMedix Inc. Receives Innovative Technology Designation From Vizient for DefenCath
Low
Report
CorMedix Inc. Receives Innovative Technology Designation From Vizient for DefenCath
10/22
04:05 pm
crmd
Halper Sadeh LLC Encourages CorMedix Inc. Shareholders to Contact the Firm to Discuss Their Rights
Low
Report
Halper Sadeh LLC Encourages CorMedix Inc. Shareholders to Contact the Firm to Discuss Their Rights
10/21
08:45 am
crmd
CorMedix (NASDAQ:CRMD) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
Medium
Report
CorMedix (NASDAQ:CRMD) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
10/21
07:27 am
crmd
CorMedix (NASDAQ:CRMD) was upgraded by analysts at D Boral Capital from a "hold" rating to a "strong-buy" rating.
Medium
Report
CorMedix (NASDAQ:CRMD) was upgraded by analysts at D Boral Capital from a "hold" rating to a "strong-buy" rating.
10/20
09:08 am
crmd
CorMedix (NASDAQ:CRMD) was upgraded by analysts at D. Boral Capital from a "hold" rating to a "buy" rating. They now have a $14.00 price target on the stock.
Medium
Report
CorMedix (NASDAQ:CRMD) was upgraded by analysts at D. Boral Capital from a "hold" rating to a "buy" rating. They now have a $14.00 price target on the stock.
10/20
07:30 am
crmd
CorMedix Inc. Announces Preliminary Third Quarter 2025 Results and Raises 2025 Net Revenue Guidance
High
Report
CorMedix Inc. Announces Preliminary Third Quarter 2025 Results and Raises 2025 Net Revenue Guidance